Authorization

Poxel Announces First Quarter 2019 Financial Update

POXEL
SA (Euronext a?? POXEL - FR0012432516), a biopharmaceutical company
focused on the development of innovative treatments for metabolic
disorders, including type 2 diabetes and non-alcoholic steatohepatitis
(NASH), today announced its cash position and revenue for the first
quarter ended March 31, 2019.


As of March 31, 2019, cash and cash equivalents were EUR 59.0 million
(USD 66.3 million), as compared with EUR 66.7 million (USD 76.4) as of
December 31,2018.




































































EUR millions
























Q1 2019
























Q4 2018



























































Cash
























3.7
























7.3








Cash equivalents
























55.3
























59.4









Total cash and cash equivalents*


























59.0
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Февраль 2020    »
ПнВтСрЧтПтСбВс
 12
3456789
10111213141516
17181920212223
242526272829